Kornimate/medical-research-clean huggingface dataset:
chewing performance level and gross motor function in children with cerebral palsy

Conditions: Cerebral Palsy; Chewing Problem; Gross Motor Development Delay

Summary: the purpose of this study is to determine the association between gross motor function and chewing performance level in children with cerebral palsy (cp). a cross-sectional study was conducted in 152 children (ages 2-10y, 51.3% male) with a diagnosis of spastic cp. the gross motor function classification system (gmfcs) was used to determine gross motor function levels of children. chewing performance level was determined by using the karaduman chewing performance scale (kcps).

the purpose of this study is to determine the association between gross motor function and chewing performance level in children with cerebral palsy (cp). a cross-sectional study was conducted in 152 children (ages 2-10y, 51.3% male) with a diagnosis of spastic cp. the gross motor function classification system (gmfcs) was used to determine gross motor function levels of children. chewing performance level was determined by using the karaduman chewing performance scale (kcps).children with a diagnosis of spastic cp aged 2 to 12 years who were referred due to chewing/swallowing problems by pediatric neurologists were included. the inclusion criteria were above the age of 24 months, and had complaints about chewing function. children under the age of 24 months, requiring tube feeding or taking any oral nutritional supplements, and used any medicine and/or oral appliances that could affect the chewing performance, were excluded.

Eligibility criteria:
inclusion criteria: * above the age of 24 months * having complaints about chewing function. exclusion criteria: * under the age of 24 months * requiring tube feeding or taking any oral nutritional supplements * using any medicine and/or oral appliances

Keywords: chewing cerebral palsy chewing disorders gross motor function
resistance exercise training for the shoulder and neck following surgery for head and neck cancer

Conditions: Head and Neck Neoplasms

Summary: the purpose of this study is to investigate the effect of a progressive therapeutic exercise program on specific physical and functional deficits in the neck and shoulder region occurring as a result of head and neck cancer treatment.

we will be conducting a randomized controlled trial to evaluate the effects of progressive resistance exercise training (pret) on shoulder and neck dysfunction due to spinal accessory neurapraxia/ neurectomy in patients with head and neck cancer. sixty-four head and neck cancer survivors will be randomly assigned to pret or standard care. participants assigned to the pret group will exercise 3 times per week for 12 weeks. the goal of the exercise program will be to enhance scapular stability, and improve mobility and strength of the upper extremity. the resistance exercise program will be progressive in terms of the number of sets and repetitions performed, as well as amount lifted, depending on baseline strength levels and overall performance status. the primary outcomes for the study include pain and dysfunction, active and passive range of motion measures, strength and endurance testing, and quality of life. nerve conduction testing and electromyography will be performed to assess/ monitor the status of the spinal accessory nerve and trapezius muscle function respectively.

Eligibility criteria:
inclusion criteria: 1. squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx or squamous cell carcinoma metastatic to the neck from unknown primary site; probable occult mucosal origin in the head and neck 2. surgical treatment includes radical neck dissection, modified radical neck dissection and other variants of functional/selective neck dissection 3. karnofsky performance status greater than or equal to 60% 4. no evidence of residual cancer in the neck and no distant (m0) metastasis 5. participants must have completed their head and neck cancer treatment exclusion criteria: 1. a history of shoulder or neck pathology unrelated to cancer treatment 2. serious co-morbid medical illness or psychiatric illness

Keywords: exercise rehabilitation head and neck neoplasms
the clinical trial of cl2020 cells for neonatal hypoxic ischemic encephalopathy

Conditions: Hypoxia-Ischemia, Brain

Summary: the purpose of this study is to evaluate the safety and the tolerability of cl2020 cells in hypoxic ischemic encephalopathy neonates with hypothermia therapy. in addition, we will evaluate the efficacy of cl2020 cells for infant development.


Eligibility criteria:
inclusion criteria: 1. at least 36 weeks gestation, and either one of the following criteria (i.-iii.) i. apgar score ≤5 at 10 minutes ii. continued resuscitation for at least 10 minutes iii. ph \<7.0 or base deficit ≥16 mmol/l in any blood sample obtained within 60 min of birth 2. moderate or severe encephalopathy by a sarnat criteria 3. undergone therapeutic hypothermia started before six hours of birth, and done for 72 hours continuously 4. birth weight ≥1,800 g 5. heart rate ≥100/min, and spo2 ≥90 % 6. able to provide voluntary written consent after receiving adequate information about the study (consent will be obtained from an acceptable representative) exclusion criteria: 1. suspected or confirmed severe congenital abnormalities or chromosomal anomaly 2. planned to undergo surgery or radiation therapy 3. scheduled to take systemic corticosteroids treatment for over five days 4. blood glucose ≥ 200 mg/dl 5. participation in another clinical study (not exclude patients in observational studies) 6. suspected or confirmed active and severe infection 7. positive for hbs antigen, hcv antibody, hiv antibody, htlv-1 antibody or syphilis serum reaction 8. history of severe hypersensitivity or anaphylactic reaction 9. severe complications

Keywords: hypoxia-ischemia, brain infant, newborn mesenchymal stem cells
a study of acne treatment in children ages 9 to 11

Conditions: Acne Vulgaris

Summary: a study to determine if using retin-a micro 0.04% as facial acne treatment in patients ages 9 to 11 is safe and efficacious.

approximately 100 female and male subjects, aged from 9 to 11 years of age, will be enrolled in this randomized, double blind, multi-center study. following satisfaction of entry criteria and screening procedures, subjects will receive either retin-a micro 0.04% or a color matched gel vehicle for once daily use during the 12-week treatment period. subjects will be monitored for safety throughout the study and for signs and symptoms of local irritation at baseline, and at weeks 2, 4, 6, 8, 10 and again at study completion, week 12. efficacy will be assessed by facial lesion counts and by utilizing scales for investigator's global evaluation of acne severity (iga #1 and iga #2) and investigator's global assessment of improvement (iga #3). all efficacy parameters with the exception of iga #3 will be measured at baseline and weeks 2, 4, 6, 8, 10 and 12. the investigator's global assessment of improvement (iga #3) will be done at week 12 only. at selected sites, photographs will be taken at baseline and weeks 2, 4, 8 and 12.

Eligibility criteria:
inclusion criteria: * males and non-pregnant, non-nursing females, 9 to 11 years, with facial pediatric acne vulgaris * minimum of 20 non-inflammatory lesions (open and closed comedones) * minimum of 30 total facial lesions (sum of inflammatory and non-inflammatory) * must have at least a rating of grade 3 on the investigator global assessment scale for acne severity (iga #1) at baseline exclusion criteria: * known sensitivity to any of the ingredients in the study medication; * any nodulocystic acne lesions * use of acne devices or systemic therapy with antibiotics within two months prior to start and throughout the duration of the study * use of systemic therapy with retinoids within four months prior to study start and throughout the duration of the study * topical use of topical retinoids within two weeks prior to study start and throughout the duration of the study * topical use of antibiotics, steroids and/or other non-retinoid topical acne products within two weeks prior to study start and throughout the duration of the study * use of an experimental drug or device within 60 days prior to study start; * use of hormonal therapy within 3 months prior to study start * history of evidence of other skin conditions or diseases that may require concurrent therapy or may interfere with the evaluation of the study medication * any significant medical conditions that could confound the interpretation of the study * history of/or current facial skin cancer * inability to refrain from use of all facial products other than those supplied by the study, while participating in the study * no use of tanning booths, sun lamps, etc. * subject is a family member of the employee or the investigator

Keywords: acne irritation objective sensory methods
screening protocol to evaluate acid alpha-glucosidase (gaa) activity and gaa gene mutations in patients with late onset pompe disease

Conditions: Pompe Disease

Summary: pompe disease (also known as glycogen storage disease type ii) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (gaa). normally, gaa is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. in patients with pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. the primary objective of this study is to identify potential candidates for future clinical studies in pompe disease.


Eligibility criteria:
inclusion criteria: * must provide written informed consent prior to any study-related procedures being performed * clinical presentation consistent with late-onset pompe disease, or a current clinical diagnosis of late-onset pompe disease * must be greater than or equal to 8 years of age * must be able to ambulate (use of assistive devices, such as a walker, cane or crutches, is permitted) exclusion criteria: * requires the use of invasive ventilatory support * requires the use of noninvasive ventilatory support while awake and in an upright position * use of any investigational product within 30 days prior to study enrollment * unwillingness to comply with protocol requirements * has clinically significant organic disease, unstable medical condition, serious or intercurrent illness * is pregnant or lactating * has participated in the prospective observational study in patients with late-onset pompe disease (aglu02303, "lopos")

Keywords: glycogen storage disease type ii gsd-ii pompe disease pompe disease (late-onset) glycogen storage disease type ii (gsd-ii) acid maltase deficiency glycogenosis 2
pulmonary hypertension in extremely preterm infants

Conditions: Bronchopulmonary Dysplasia; Pulmonary Hypertension; Premature Birth

Summary: extremely preterm infants are at risk for developing bronchopulmonary dysplasia (bpd) and associated chronic pulmonary hypertension (ph), a consequence of altered pulmonary vasculature. this condition occurs in about 25% of babies with bpd, and the association grows with increasing bpd severity. other risk factors have been described as well. morbidity and mortality associated with prematurity and/or bpd increase significantly in the presence of ph. thus, international guidelines encourage the use of standardized screening protocols for this condition. however, several questions regarding these recommendations are left unanswered, such as a clear definition for ph in this population. the research aim is to prospectively evaluate prevalence, risk factors and clinical course of ph in these children. the investigators aim to identify at-risk infants early on and ultimately improve survival making use of an early targeted intervention.


Eligibility criteria:
inclusion criteria: preterm infants with * gestational age \<28 0/7 weeks * birth weight \<1000 grams exclusion criteria: * major congenital malformations * structural airway or lung disease * congenital heart disease * lack of parental consent
analysis of factors and treatment related to chronic cough after pulmonary resection

Conditions: Persistent Cough; Pneumonectomy; Lung Neoplasms

Summary: surgical resection is the primary treatment for pulmonary tumors. surgeons has been frequently concerned about effectiveness, safety, and minimal invasive techniques. however, persistent cough, one of the most common complications of lung surgery, has received insufficient attention. this study set out to investigate the risk factors and treatment related to persistent cough after pulmonary resection.


Eligibility criteria:
inclusion criteria: 1. patients who received pulmonary resection; 2. 18-to 85-year-old; 3. pathologically diagnosed as nsclc or benign tumor. exclusion criteria: 1. multiple malignancy in other parts of body; 2. refuse to participate in this study; 3. other situations evaluated by investigators not meet the enrollment.
reach study (recovery environments: assessing cognitive & brain health in community mental health)

Conditions: Schizophrenia; Schizo Affective Disorder; Schizophreniform Disorders

Summary: the purpose of this study is to understand how different types of community-based mental health care affect thinking abilities, daily functioning, and brain activity in adults with schizophrenia and related conditions. the investigators are especially interested in learning whether the clubhouse model-a structured, supportive community for individuals with mental illness-has unique benefits compared to standard outpatient mental health services. if participants decide to join, they will be asked to complete a total of six study visits with the research team over the course of your participation. three of these study visits are at the beginning (baseline) and the remaining three are six months later. two of the three visits will includes interviews, questionnaires, and thinking and memory tasks (cognitive testing) and one session will be an mri brain scan, which is a safe and non-invasive imaging procedure. the total time required for each visit will be approximately 90 minutes to two hours. participants may take breaks as needed.


Eligibility criteria:
inclusion criteria: * (1) have a dsm-v diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform confirmed by diagnostic assessment and medical record review * (2) between the ages of 18-50 * (3) stabilized on psychotropic medication as indicated by no changes to the primary psychiatric medication in the last month * (4) able to read and speak fluent english at a sixth grade level or higher for purposes of informed consent and cognitive testing * for clubhouse members, they must be a first-time, newly enrolled member exclusion criteria: * (1) had previous membership at a clubhouse (magnolia or elsewhere) * (2) have a current severe substance use disorder * (3) have persistent suicidal or homicidal behavior * (4) a co-occurring diagnosis of an intellectual or learning disability or neurodevelopment condition (e.g., autism; based on chart review) * (5) had recent psychiatric instability requiring hospitalization in the past month; * (6) history of a traumatic brain injury (tbi; based on record review) * (7) contraindicators for mri (e.g., pacemaker, claustrophobia) * participants in the usual care will be excluded if they are a current clubhouse member or join a clubhouse during participation in this research

Keywords: clubhouse model of psychosocial rehabilitation community mental health interventions cognition brain functioning
metabolic insights: the impact of f-18 fdg pet/ct in adult lymphoma

Conditions: Lymphoma

Summary: 1. to assess staging accuracy of f-18 fdg pet/ct in lymphoma 2. determine the role of f-18 fdg pet/ct in monitoring treatment response and detecting relapse or residual disease in lymphoma 3. to evaluate fdg uptake correlation with histopathological subtypes and immunophenotypes as a prognostic factor.

the incidence of lymphoma in egypt has been increasing in recent years, with a noticeable rise in both hodgkin's and non-hodgkin's lymphoma cases. this increase is due to better healthcare, awareness, and diagnostic advancements. risk factors include infections, lifestyle, genetics, and immune system issues. lymphoma is now the fourth most prevalent cancer among egyptian adults, accounting for approximately 8.4% of all new cancer cases annually. as the burden of lymphoma grows, it becomes essential to develop effective strategies for its diagnosis and management. flurodeoxyglucose f-18 (f-18 fdg) is a radiolabeled glucose analog that accumulates in metabolically active cells, such as lymphoma cells, making f-18 fdg positron emission tomography / computed tomography scan (pet/ct) highly sensitive for detecting malignant lesions. it plays a key role in staging lymphoma by assessing the extent of disease spread. additionally, f-18 fdg pet/ct is essential for assessing treatment response, detecting relapses early, and evaluating the prognosis of patients, offering prognostic value by evaluating residual disease and predicting recurrence. its ability to monitor disease progression and detect recurrent lymphoma provides critical insights that guide therapeutic decisions and long-term outcomes.

Eligibility criteria:
inclusion criteria: * age: patient must be older than 18 years. * confirmed diagnosis of lymphoma: patient must have a confirmed diagnosis of lymphoma based on histopathology and immunophenotyping. exclusion criteria: * patients with known concomitant malignancy. * pregnancy: pregnant women due to the potential risks associated with radiation exposure from the pet/ct scan. * severe renal or hepatic impairment: patients with significant renal or hepatic dysfunction that could affect fdg metabolism or excretion. * uncontrolled diabetes: patients with uncontrolled diabetes (blood glucose \>200 mg/dl), as it can affect fdg uptake and pet/ct results.

Keywords: 18 fdg pet ct lymphoma
effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this trial is conducted in the united states of america (usa). the purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting (ibt-cms: intensive behaviour therapy for obesity in a primary care setting according to centers for medicare \& medicaid services (cms) visit schedule).


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities. trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * bmi above or equal to 30 kg/m\^2 * male or female, age 18 years or older at the time of signing informed consent exclusion criteria: * hba1c (glycosylated haemoglobin) above or equal to 6.5% (at screening visit), or diagnosis of type 1 or type 2 diabetes mellitus * recent history of cardiovascular disease (myocardial infarction or stroke within the past 6 months), severe congestive heart failure (nyha class iii, iv), or second degree or greater heart block * personal or family history of medullary thyroid carcinoma (mtc), or multiple endocrine neoplasia type 2 (men2) * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice) * use in past 90 days of medications known to induce significant weight loss (e.g., prescription weight loss medications) or weight gain (e.g., chronic use of oral steroids, second generation antipsychotics) * history of pancreatitis (acute or chronic) * history of major depressive disorder within the past 2 years * any lifetime history of a suicide attempt * inadequately treated blood pressure defined as grade 3 hypertension or higher (systolic above or equal to 180 mmhg or diastolic above or equal to 110 mmhg) * history of malignancy (except for non-melanoma skin cancer) within the past 5 years
an observational cohort study to evaluate the safety and efficacy of micardis tablets taken once daily at 40 mg/day and 80 mg/day in hypertensive patients under real life conditions in usual clinical practice

Conditions: Hypertension

Summary: the "control" study is an out patient based prospective observational cohort study. the main aim of the study is to survey the safety and efficacy of micardis 40 mg/day and 80 mg/day under real life conditions in usual clinical practice in essential hypertensive patients in the kingdom of saudi arabia. the patients participating in the study will be surveyed for 24 weeks.


Eligibility criteria:
inclusion criteria: * male or female. * aged 20 to 80 years old. * adult essential hypertensive either newly diagnosed and untreated, or previously treated and uncontrolled patients; sitting blood pressure: systolic bp \> 140 mmhg but \ 90 mmhg but \< 110 mmhg). * patients who are assessed to benefit from the intake of angiotensin ii receptor blocker (arb) monotherapy or as add-on medication. exclusion criteria: * patients with contraindications to telmisartan use (as per the micardis® tablets package insert). * known hypersensitivity to the active ingredient or to any of the excipients of micardis® tablets. * any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications. * patients participating in any other protocol
adapted physical activity program (apa) for effort rehabilitation of children and teenagers with marfan syndrome

Conditions: Marfan Syndrome

Summary: this research study aims to evaluate the effect of a 6-month adapted physical activity program (apa) on the endurance capacities (evaluated as the maximum oxygen consumption \[vo2 peak\] on a cardiopulmonary exercise test) of children and adolescents with marfan syndrome or related.

marfan syndrome (mfs) is characterized by the association of multisystem damage related to connective tissue fragility. the risk of aortic dissection has diverted attention from significant musculoskeletal damage despite commonly reported extreme fatigue and pain with impact on the patient's quality of life. in a recent study (marfanpower, nct03236571), investigators have observed reduced endurance capacities in children and teenagers with mfs (average vo2 peak at 60% of expected), which were significantly increased by an intensive rehabilitation program. based on this experience, investigators aim to evaluate the effect of a physical activity program adapted to the daily life of the young patients on their endurance capacities and their quality of life. this program will be set up by an adapted physical activity (apa) coach after a complete assessment, including a cardiopulmonary exercise test with vo2 peak measurement, which will be carried out in the reference centre for marfan syndrome at the toulouse university hospital. the vo2 peak evolution will be evaluated after 6 months of program. this is a recognized parameter for the evaluation of endurance and has been validated in children. investigators hypothesize that the implementation of a physical activity program adapted to the daily life and interests of the child with mfs will efficiently improve endurance, prevent deconditioning and promote long term benefits.

Eligibility criteria:
inclusion criteria: * genetically confirmed marfan syndrome or related syndrome * girl or boy aged 7 to 17 * informed and written consent signed by at least one of the two holders of parental authority * patient affiliated to a social security scheme or equivalent exclusion criteria: * cardiac contraindications to the apa program: * severe aortic dilation (aortic diameter \> 45 mm) * and/or left ventricular failure (left ventricular ejection fraction \<45%) * and/or severe mitral leakage ≥ grade 3 * pregnancy